Filing Overview
Registrant: Brilliant Acquisition Corporation, although the request metadata identifies T3 Defense Inc. The Form 8-K reports an event dated June 23, 2023 and was signed June 26, 2023. The filing concerns a proposed business combination with Nukkleus Inc., not operating results for T3 Defense.
Business Context and Transaction
Brilliant, Nukkleus and BRIL Merger Sub, Inc. entered into an Amended and Restated Agreement and Plan of Merger on June 23, 2023. Brilliant will first redomicile from the British Virgin Islands to Delaware. Following the domestication, Merger Sub will merge with and into Nukkleus, with Nukkleus surviving as a wholly owned subsidiary of Brilliant. The combined company is expected to operate as a Nasdaq-listed entity.
- Nukkleus stockholders will receive a pro rata portion of 14,000,000 shares of Brilliant common stock.
- Nukkleus options will be assumed and converted using a 1:26.227 exchange ratio, with adjusted share amounts and exercise prices.
- Existing Brilliant shares, rights and warrants will remain outstanding and become substantially identical Delaware securities.
- Eligible public holders of Brilliant securities may receive additional shares or warrants from a Backstop Pool, generally capped at the lower of 1,012,000 shares or 40% of the relevant public shares and rights.
Financial Metrics and Liquidity
This Form 8-K does not report revenue, profit, cash flow, margins, debt, cash balances, trust-account balances or other operating financial metrics. The filing states that completion is subject to, among other conditions, satisfaction of a minimum trust-account amount after shareholder redemptions.
Material Changes Versus Prior Agreement
- The transaction structure changed from a merger in which Brilliant would have become a wholly owned subsidiary of Nukkleus to a domestication of Brilliant followed by a merger in which Nukkleus will become a wholly owned subsidiary of Brilliant.
- The outside closing date was extended to the later of July 23, 2023 or an approved extension date, but no later than December 23, 2023.
- The Support Agreement, Lock-Up Agreement and Registration Rights Agreement forms were revised to reflect the new transaction structure.
- Other terms are described as materially consistent with the original agreement.
Outlook, Risks and Contingencies
Closing remains subject to shareholder approvals, satisfaction of the minimum trust-account condition following redemptions, required governmental and regulatory approvals, and other customary closing conditions. The transaction may not close by the applicable deadline, and Brilliant may need shareholder approval to extend its corporate existence.
Material risks identified include failure to complete the transaction, possible legal proceedings, difficulty maintaining Nasdaq listing, disruption to Nukkleus’s business and employee retention, changes in regulation and competitive conditions, volatility in the securities, integration and commercialization challenges, and failure to execute post-closing business plans.
Brilliant expects to file a Form S-4 registration statement containing a proxy statement/prospectus. Investors are directed to review that filing and subsequent amendments before making voting or investment decisions.
Key Facts to Verify
- Whether Brilliant and Nukkleus obtain all required shareholder and regulatory approvals.
- The amount remaining in Brilliant’s trust account after redemptions and whether the minimum trust-account condition is satisfied.
- Whether the business combination closes by the applicable deadline, including any approved extension.
- The final share issuance, Backstop Pool allocation, option conversion and warrant adjustments.
- The final Form S-4, proxy statement/prospectus and related risk factors.
- The discrepancy between the requested company name, T3 Defense Inc., and the filing registrant, Brilliant Acquisition Corporation.